Research Analysts Set Expectations for HRMY Q2 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities research analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for shares of Harmony Biosciences in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $0.87 per share for the quarter, down from their prior estimate of $0.90. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.19. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $184.73 million during the quarter, compared to analysts’ expectations of $184.26 million. During the same quarter last year, the company posted $0.67 earnings per share. Harmony Biosciences’s quarterly revenue was up 19.5% on a year-over-year basis.

Other equities analysts have also recently issued research reports about the company. Needham & Company LLC reiterated a “buy” rating and set a $49.00 price target on shares of Harmony Biosciences in a report on Tuesday, May 6th. Mizuho raised their price objective on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research report on Tuesday, February 11th. They set a “buy” rating and a $55.00 price objective for the company. Finally, UBS Group cut their price objective on shares of Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating for the company in a research report on Monday, April 28th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $52.33.

Harmony Biosciences Trading Down 3.6%

Harmony Biosciences stock opened at $34.37 on Monday. Harmony Biosciences has a 52 week low of $26.47 and a 52 week high of $41.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The stock has a market capitalization of $1.97 billion, a P/E ratio of 16.29, a PEG ratio of 0.47 and a beta of 0.82. The stock has a 50-day simple moving average of $31.42 and a 200 day simple moving average of $34.02.

Institutional Trading of Harmony Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Financial Management Professionals Inc. acquired a new stake in Harmony Biosciences during the 1st quarter worth about $29,000. GAMMA Investing LLC boosted its position in shares of Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after purchasing an additional 436 shares in the last quarter. Mendota Financial Group LLC lifted its position in Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after acquiring an additional 965 shares in the last quarter. Brooklyn Investment Group lifted its position in Harmony Biosciences by 1,031.9% in the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company’s stock valued at $35,000 after acquiring an additional 970 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in Harmony Biosciences in the 4th quarter valued at about $41,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.